Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association

Anaemia is a common complication of chronic kidney disease (CKD) and is associated with poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis-stimulating agents (ESAs) and blood transfusions has been the mainstay for treatment of anaemia in CKD for more than 3 dec...

Descripción completa

Detalles Bibliográficos
Autores: Stoumpos, Sokratis, Crowe, Kirsty, Sarafidis, Pantelis, Barratt, Jonathan, Bolignano, Davide, Vecchio, Lucia Del, Małyszko, Jolanta, Więcek, Andrzej, Ortiz Arduán, Alberto, Cozzolino, Mario
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/720769
Acceso en línea:http://hdl.handle.net/10486/720769
https://dx.doi.org/10.1093/ndt/gfae075
Access Level:acceso abierto
Palabra clave:anaemia
chronic kidney disease
erythropoiesis-stimulating agents
erythropoietin
hypoxia-inducible factor prolyl hydroxylase inhibitors
Medicina
id ES_3bee8c037cf09f31d45fd78db240d4d2
oai_identifier_str oai:repositorio.uam.es:10486/720769
network_acronym_str ES
network_name_str España
repository_id_str
spelling Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal AssociationStoumpos, SokratisCrowe, KirstySarafidis, PantelisBarratt, JonathanBolignano, DavideVecchio, Lucia DelMałyszko, JolantaWięcek, AndrzejOrtiz Arduán, AlbertoCozzolino, Marioanaemiachronic kidney diseaseerythropoiesis-stimulating agentserythropoietinhypoxia-inducible factor prolyl hydroxylase inhibitorsMedicinaAnaemia is a common complication of chronic kidney disease (CKD) and is associated with poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis-stimulating agents (ESAs) and blood transfusions has been the mainstay for treatment of anaemia in CKD for more than 3 decades. Despite available treatments, CKD patients with anaemia are undertreated and moderate–severe anaemia remains prevalent in the CKD population. Anaemia has consistently been associated with greater mortality, hospitalization, cardiovascular events and CKD progression in CKD patients, and the risk increases with anaemia severity. Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors have a novel mechanism of action by mimicking the body’s response to hypoxia and have emerged as an alternative to ESAs for treatment of anaemia in CKD. Their efficacy in correcting and maintaining haemoglobin has been demonstrated in >30 phase 3 clinical trials. Additionally, HIF activation results in various pleiotropic effects beyond erythropoiesis, with cholesterol reduction and improved iron homeostasis and potential anti-inflammatory effects. The long-term safety of these agents, particularly with respect to cardiovascular and thromboembolic events, and their possible effect on tumour growth needs to be fully elucidated. This article presents in detail the effects of HIF-PH inhibitors, describes their mechanisms of action and pharmacologic properties and discusses their place in the treatment of anaemia in CKD according to the available evidenceSS research is funded by the Chief Scientific Officer (CSO), Scotland. AO research is supported by FIS/Fondos FEDER (PI22/00469, PI22/00050, PI21/00251, ERA-PerMed-JTC2022 (SPAREKID AC22/00027), FRIAT, Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA_COR-CM. Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR) and SPACKDc PMP21/00109, FEDER funds, COST Action PERMEDIK CA21165, supported by COST (European Cooperation in Science and Technology) 2023-2027 and PREVENTCKD Consortium Project ID: 101101220 Programme: EU4H DG/Agency: HADEA.Oxford University Press20242024-10-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/720769https://dx.doi.org/10.1093/ndt/gfae075reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/7207692026-06-23T12:46:27Z
dc.title.none.fl_str_mv Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
title Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
spellingShingle Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
Stoumpos, Sokratis
anaemia
chronic kidney disease
erythropoiesis-stimulating agents
erythropoietin
hypoxia-inducible factor prolyl hydroxylase inhibitors
Medicina
title_short Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
title_full Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
title_fullStr Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
title_full_unstemmed Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
title_sort Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association
dc.creator.none.fl_str_mv Stoumpos, Sokratis
Crowe, Kirsty
Sarafidis, Pantelis
Barratt, Jonathan
Bolignano, Davide
Vecchio, Lucia Del
Małyszko, Jolanta
Więcek, Andrzej
Ortiz Arduán, Alberto
Cozzolino, Mario
author Stoumpos, Sokratis
author_facet Stoumpos, Sokratis
Crowe, Kirsty
Sarafidis, Pantelis
Barratt, Jonathan
Bolignano, Davide
Vecchio, Lucia Del
Małyszko, Jolanta
Więcek, Andrzej
Ortiz Arduán, Alberto
Cozzolino, Mario
author_role author
author2 Crowe, Kirsty
Sarafidis, Pantelis
Barratt, Jonathan
Bolignano, Davide
Vecchio, Lucia Del
Małyszko, Jolanta
Więcek, Andrzej
Ortiz Arduán, Alberto
Cozzolino, Mario
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv anaemia
chronic kidney disease
erythropoiesis-stimulating agents
erythropoietin
hypoxia-inducible factor prolyl hydroxylase inhibitors
Medicina
topic anaemia
chronic kidney disease
erythropoiesis-stimulating agents
erythropoietin
hypoxia-inducible factor prolyl hydroxylase inhibitors
Medicina
description Anaemia is a common complication of chronic kidney disease (CKD) and is associated with poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis-stimulating agents (ESAs) and blood transfusions has been the mainstay for treatment of anaemia in CKD for more than 3 decades. Despite available treatments, CKD patients with anaemia are undertreated and moderate–severe anaemia remains prevalent in the CKD population. Anaemia has consistently been associated with greater mortality, hospitalization, cardiovascular events and CKD progression in CKD patients, and the risk increases with anaemia severity. Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors have a novel mechanism of action by mimicking the body’s response to hypoxia and have emerged as an alternative to ESAs for treatment of anaemia in CKD. Their efficacy in correcting and maintaining haemoglobin has been demonstrated in >30 phase 3 clinical trials. Additionally, HIF activation results in various pleiotropic effects beyond erythropoiesis, with cholesterol reduction and improved iron homeostasis and potential anti-inflammatory effects. The long-term safety of these agents, particularly with respect to cardiovascular and thromboembolic events, and their possible effect on tumour growth needs to be fully elucidated. This article presents in detail the effects of HIF-PH inhibitors, describes their mechanisms of action and pharmacologic properties and discusses their place in the treatment of anaemia in CKD according to the available evidence
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-10-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/720769
https://dx.doi.org/10.1093/ndt/gfae075
url http://hdl.handle.net/10486/720769
https://dx.doi.org/10.1093/ndt/gfae075
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406337477115904
score 15,812429

Similares en LA Referencia